N/A N=10 Transcranial Magnetic Stimulation for Children With Tourette's Syndrome
Tourette Syndrome
Primary: Yale Global Tic Severity Scale — 64.40; 26.40 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=20 An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome.
Tourette Syndrome
Primary: Change in TTS — -14.29 units on a scale
Phase 2 N=18 Ecopipam Treatment of Tourette Syndrome
Tourette's Syndrome
Primary: Yale Global Tic Severity Score — 25.3 units on a scale
N/A N=10 Response Inhibition in Tourette Syndrome
Tourette Syndrome
Primary: Stop Signal Reaction Time (SSRT) — 249; 245 milliseconds — p=0.49
Phase 4 N=30 Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
Tourette Syndrome
Primary: The Change From Baseline to 6-week Scores for The Total Tic Subscale (TTS) — 6.2; 10.5; 10.2 units on a scale
Phase 3 N=29 A Randomized, Placebo-controlled, Tourette Syndrome Study.
Tourette Syndrome
Primary: Change From Baseline in Total Tic Score at Day 70 — -5.0; -14.29 units on a scale — p=0.0259
Phase 3 N=61 Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder
Chronic Motor or Vocal Tic Disorder · Tourette's Disorder
Primary: Mean Change of Total Tic Scores in K-YGTSS From Randomization (Baseline, Visit 2) to the Final Visit (Visit 7) — -9.62; -14.97 units on a scale
Phase 4 N=11 Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder
Tourette's Syndrome · Tic Disorders
Primary: Calculating Difference Between Means (Baseline and Endpoint Scores on the Yale Global Tic Severity Scale Subscales) — 15.82; 9.73; 12.36; 7.00 units on a scale — p=<.05
Phase 3 N=135 Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
Tourette's Disorder
Primary: Change From Baseline in Yale Global Tic Severity Scale (YGTSS) - Total Tic Score (TTS) — -12.34; -7.72 score on a scale — p==0.0028
Phase 2 N=63 Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria
Tourette Syndrome
Primary: Mean Change From Baseline in Total Tic Score of the Yale Global Tic Severity Scale — -7.17; -7.16 score on a scale — p=0.996
Phase 2 N=28 Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
Tourette Syndrome
Primary: Total Tic Severity Score (Part 2 Only) Crossover Analysis Over 6 Periods — 24.32; 25.41; 22.99 Total Tic Severity Score — p=0.0087
Phase 2 N=4 Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's Disorder
Tourette's Disorder
Primary: Global Severity Score on the Y-GTSS — 80.25; 78.75; 61; 69.75 units on a scale
Phase 3 N=110 Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
Tourette's Disorder · Tic Disorder
Primary: Percentage of Participants With Adverse Events. — 76.4; 4.5; 3.6 Percentage of participants
N/A N=21 Proof of Concept Study of an Oral Orthotic to Reduce Tic Severity in Chronic Tic Disorder and Tourette Syndrome
Tourette Syndrome · Chronic Tic Disorder
Primary: Change in Global Severity of Tics and Clinical Condition as Measured by YGTSS — 20.19; 25.82 score on a scale
Phase 3 N=83 Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)
Tourette's Disorder
Primary: Mean Change From Baseline to Week 8 in Yale Global Tic Severity Scale (YGTSS) Total Tic Score — -8.2; -9.9; -14.5; -9.6 score on scale